On Aug. 2, 2024, Inspire Medical Systems announced it received FDA approval for the Inspire V therapy system.
About Inspire V System
Inspire upper airway stimulation is used to treat patients with moderate to severe obstructive sleep apnea (OSA) who cannot tolerate PAP treatments and who do not have a complete concentric collapse at the soft palate level.
Inspire therapy is a surgical solution. The system includes an implant that keeps the patient’s airway open while sleeping, a remote to turn on therapy when sleeping, and an app to track and share sleep data with a medical professional. The implant is placed near the patient’s collarbone during an outpatient procedure.
The latest FDA approval is for the company’s next-generation Inspire V therapy system, which includes an updated neurostimulator and Bluetooth-enabled patient remote and physician programmer.
According to the press release, the company is focused on manufacturing products and establishing inventory levels and is targeting a full launch in 2025.
Inspire therapy is the first and only FDA-approved neurostimulation technology to treat moderate to severe OSA.
About upper airway stimulation therapy
Upper airway stimulation therapy, a surgical solution for sleep apnea, involves the implantation of a device near the neck and chest that stimulates the hypoglossal nerve to keep the airway open during sleep, providing an alternative for those unable to tolerate CPAP or oral appliances.
Read more industry news from the AASM.
